Full Length Research Paper
Biomarkers are considered as an innovative tool in the diagnosis and follow-up of breast cancer. The aim of the study was to assess the profile of circulating tumour markers CA 15-3 and CEA in patients under chemotherapy for breast cancer in Ouagadougou. This is a prospective cross-sectional study with a descriptive and analytical aims which was done from July to November 2020. Patients with histologically confirmed malignant breast tumour and under chemotherapy were included. Results revealed that the study was on thirty (30) female patients whose average age was 47.47 ± 2.10 years with a mean BMI of 27.29 ± 1.09 kg/m2. It was a non-specific type of infiltrating carcinoma with SBRm II grade in 90% of the patients. The mean CA 15-3 was 212.98 U/mL before chemotherapy and 165.75 U/mL after it. The CEA mean value was 3.13 ng/L before chemotherapy and 16.14 ng/L after it. Serum CA 15-3 was significantly associated with tumour site, SBRm grade, chemotherapy line and treatment response. Serum CEA level was significantly associated with tumour site and SBRm grade. Despite their lack of sensitivity, tumour markers, particularly CA 15-3 enabled assessment of the response to treatment in patients in this study.
Key words: Tumour markers, CA 15-3, CEA, breast cancer, chemotherapy.
Copyright © 2023 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0